[HTML][HTML] Outcome of patients with non–small cell lung cancer and brain metastases treated with checkpoint inhibitors
…, J Mazieres, C Lefebvre, A Rabeau… - Journal of Thoracic …, 2019 - Elsevier
Introduction Although frequent in NSCLC, patients with brain metastases (BMs) are often
excluded from immune checkpoint inhibitor (ICI) trials. We evaluated BM outcome in a less-…
excluded from immune checkpoint inhibitor (ICI) trials. We evaluated BM outcome in a less-…
[HTML][HTML] A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with …
…, O Molinier, A Renault, A Rabeau… - Journal of Thoracic …, 2019 - Elsevier
Introduction This randomized phase II trial aimed at evaluating the engineered programmed
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
[HTML][HTML] Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non …
C Pasquier, L Chaltiel, C Massabeau, A Rabeau… - Frontiers in …, 2023 - frontiersin.org
Background: The optimal modalities of radiotherapy when combining concurrent chemoradiation
(CCRT) and immunotherapy (IO) for locally advanced non-small cell lung cancer (LA-…
(CCRT) and immunotherapy (IO) for locally advanced non-small cell lung cancer (LA-…
[HTML][HTML] Circulating tumor DNA as a prognostic determinant in small cell lung cancer patients receiving atezolizumab
…, P Merle, O Molinier, A Renault, A Rabeau… - Journal of Clinical …, 2020 - mdpi.com
Background: The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC).
The purpose of the present study was to determine whether circulating tumor DNA (ctDNA), …
The purpose of the present study was to determine whether circulating tumor DNA (ctDNA), …
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
…, B Asselain, T Egenod, A Rabeau… - …, 2020 - Taylor & Francis
EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness
and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). …
and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). …
Genomic instability and protumoral inflammation are associated with primary resistance to anti–PD-1+ antiangiogenesis in malignant pleural mesothelioma
…, C Baldini, A Varga, AA Yurchenko, A Rabeau… - Cancer Discovery, 2023 - AACR
Sequential explorations of fresh tumor biopsies demonstrated that mesothelioma resistance
to anti–PD-1 + antiangiogenics is not due to a lack of tumor T-cell infiltration but rather due …
to anti–PD-1 + antiangiogenics is not due to a lack of tumor T-cell infiltration but rather due …
Diffuse alveolar haemorrhage secondary to e-cigarette “vaping” associated lung injury (EVALI) in a young European consumer
…, S Ruiz, T Lanot, L Brouchet, A Rabeau… - European …, 2020 - Eur Respiratory Soc
We report the case of a 28-year-old woman admitted with acute respiratory failure. The patient
had no personal or familial medical history involving respiratory disease such as asthma, …
had no personal or familial medical history involving respiratory disease such as asthma, …
Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial
B Cabarrou, C Gomez-Roca, M Viala, A Rabeau… - Investigational new …, 2020 - Springer
In oncology clinical research, the analysis and reporting of adverse events is of major interest.
A consistent depiction of the safety profile of a new treatment is as crucial in establishing …
A consistent depiction of the safety profile of a new treatment is as crucial in establishing …
Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit
…, MN Paludetto, A Martel, S Perriat, A Rabeau… - Supportive Care in …, 2019 - Springer
Purpose Hydration is needed before and after cisplatin infusion for reducing the risk of
nephrotoxicity. Even though there is no standard regimen, patients receive mostly intravenous …
nephrotoxicity. Even though there is no standard regimen, patients receive mostly intravenous …
Bronchoscopic multimodal management of tracheal neurofibroma
A Rabeau, J Mazieres, C Hermant… - … of Bronchology & …, 2016 - journals.lww.com
… Rabeau, Audrey MD * ; Mazieres, Julien MD, PhD * ; Hermant, Christophe MD * ; Projetti,
Fabrice MD † ; Didier, Alain MD, PhD * ; Guibert, Nicolas MD * … Articles in PubMed by …
Fabrice MD † ; Didier, Alain MD, PhD * ; Guibert, Nicolas MD * … Articles in PubMed by …